SWM
BTAI icon

SeaCrest Wealth Management’s BioXcel Therapeutics BTAI Stock Holding History

SeaCrest Wealth Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-697
Closed -$4.17K – 664
2024
Q4 		$4.17K Sell
697
-75
-10% -$627 ﹤0.01% 655
2024
Q3 		$7.53K Sell
772
-212
-22% -$2.85K ﹤0.01% 651
2024
Q2 		$20.2K Sell
984
-94
-9% -$3.15K ﹤0.01% 609
2024
Q1 		$48.6K Sell
1,078
-56
-5% -$2.67K 0.01% 596
2023
Q4 		$51K Buy
1,134
+100
+10% +$5.56K 0.01% 612
2023
Q3 		$41.9K Sell
1,034
-260
-20% -$26.3K 0.01% 613
2023
Q2 		$138K Buy
1,294
+362
+39% +$121K 0.02% 596
2023
Q1 		$278K Buy
+932
New +$398K 0.04% 485

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SeaCrest Wealth Management's BTAI Position: Q1 2025 in Review

SeaCrest Wealth Management sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 697 shares — an estimated $4.17K sold.

SeaCrest Wealth Management first reported a position in BTAI in Q1 2023 and held it in 8 quarters. The position peaked at $278K in Q1 2023. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • SeaCrest Wealth Management reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SeaCrest Wealth Management sold 697 BioXcel Therapeutics shares in Q1 2025, an estimated $4.17K.
  • SeaCrest Wealth Management first reported a position in BioXcel Therapeutics in Q1 2023 and held it in 8 quarters.
  • SeaCrest Wealth Management's BioXcel Therapeutics position peaked at $278K in Q1 2023.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on SeaCrest Wealth Management's 13F filing for Q1 2025, filed 11 Apr 2025.